Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study1 Pre-specified analyses of cognitive endpoints de
Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
05:10pm, Wednesday, 13'th May 2026
Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd.
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
06:01pm, Thursday, 07'th May 2026
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Famil
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
04:01pm, Thursday, 07'th May 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings
11:57am, Thursday, 30'th Apr 2026
Biogen (NASDAQ:BIIB) reported upbeat earnings for the first quarter on Wednesday.
Filing date: April 29, 2026. Biogen Inc (BIIB) released its 8-K filing with Q1 2026 results.Total revenue was $2,477.8 million, which is above the estimated re
Why Biogen Stock Was a Winner on Wednesday
07:46pm, Wednesday, 29'th Apr 2026
The biotech's growth portfolio continues to add to its overall top line.
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
02:21pm, Wednesday, 29'th Apr 2026
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Big Boosts to Econ Growth from AI Investment, Inventories & More
11:31am, Wednesday, 29'th Apr 2026
For once, there is something even bigger than the Strait of Hormuz affecting investors' attitudes this morning.
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
11:21am, Wednesday, 29'th Apr 2026
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key Metrics
10:30am, Wednesday, 29'th Apr 2026
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates
08:10am, Wednesday, 29'th Apr 2026
Biogen Inc. (BIIB) came out with quarterly earnings of $3.57 per share, beating the Zacks Consensus Estimate of $2.95 per share. This compares to earnings of $3.02 per share a year ago.
Biogen Lowers 2026 Earnings Outlook
07:02am, Wednesday, 29'th Apr 2026
Biogen lowered its earnings guidance and projected weaker revenue for 2026, tempering the impact of a first-quarter rise in both sales and profit.
Biogen cuts annual profit forecast on acquisition-related charges
06:07am, Wednesday, 29'th Apr 2026
Biogen cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although its first-quarter earnings beat expectations on better-than-estimated sales of its Alzheimer
